Innovation in the Treatment of Thoracic Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 2256
Special Issue Editors
Interests: lung cancer; robotic surgery; mediastinal and thymus surgery; pleural surgery
Interests: lung cancer; mediastinum; minimally invasive surgery; pleural malignancy; robotic surgery
Special Issues, Collections and Topics in MDPI journals
Interests: lung cancer; malignant pleural mesothelioma; molecular pathology
Special Issues, Collections and Topics in MDPI journals
Interests: : lung cancer surgery; robotic surgery mediastinal and thymus surgery; pleural surgery
Interests: lung cancer; thoracic malignancies; chemotherapy; immunotherapy; targeted therapies; molecular profiling; personalized medicine
Special Issue Information
Dear Colleagues,
In the last years, we have been spectators of an evolution in the field of thoracic tumors treatment.
In oncologic area, target therapies and immunotherapy are modifying the disease course, obtaining an improvement of prognosis. Moreover, loco-regional treatments are focusing on increasingly minimally invasive approaches. Certainly, the innovation is the foundation of these important changes, with an impact on medical practice, patient prognosis and quality of life.
We are pleased to invite you to participate to this Special Issue on the innovation in the treatment of thoracic cancers. This special issue aims to give an overview of the most recent innovation in surgical, oncological, pathological and radiotherapy field in the treatment of lung, pleural and mediastinal tumors.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: new surgical techniques, additional application of surgical approaches, targeted and biomarker-driven treatments, precision medicine, innovation in pathological analysis, future directions in radiotherapy and technological evolution in cancer therapy.
We look forward to receiving your contributions.
Prof. Dr. Franca Melfi
Dr. Carmelina C. Zirafa
Dr. Greta Alì
Dr. Gaetano Romano
Dr. Andrea Sbrana
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung tumors
- mediastinal tumors
- pleural malignancies
- target therapies
- surgical techniques
- innovation - precision medicine